Literature DB >> 9271324

Erratum to "Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design".

P W Parren1, M C Gauduin, R A Koup, P Poignard, Q J Sattentau, P Fisicaro, D R Burton.   

Abstract

Understanding the antibody response in HIV-1 infection is important to vaccine design. We have studied the antibody response to HIV-1 envelope at the molecular level and determined the characteristics of neutralizing and non-neutralizing antibodies. These antibodies were isolated from phage display libraries prepared from long-term seropositive asymptomatic individuals. The HIV-1 envelope is presented to the immune system in several antigenically distinct configurations: unprocessed gp160, gp120 and gp41 subunits and native envelope, each of which may be important in eliciting an antibody response in HIV-1 infection. The antibodies tested characteristically had poor affinities for native envelope as expressed on the surface of virions or infected cells, but had high affinities against non-native forms of HIV-1 envelope (viral debris). An exceptionally potent neutralizing antibody in contrast, bound native envelope with equivalent or somewhat higher affinity than this. This indicates that the antibody response in HIV-1 infection is principally elicited by viral debris rather than virions, and that these antibodies bind and neutralize viruses sub-optimally. Potential vaccines should be designed to elicit responses against native envelope.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9271324     DOI: 10.1016/s0165-2478(97)00109-0

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  12 in total

1.  Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity.

Authors:  P W Parren; I Mondor; D Naniche; H J Ditzel; P J Klasse; D R Burton; Q J Sattentau
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

2.  Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1.

Authors:  M Hezareh; A J Hessell; R C Jensen; J G van de Winkel; P W Parren
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.

Authors:  M B Zwick; M Wang; P Poignard; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.

Authors:  Ralph Pantophlet; Erica Ollmann Saphire; Pascal Poignard; Paul W H I Parren; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

5.  Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

Authors:  Simon Beddows; Norbert Schülke; Marc Kirschner; Kelly Barnes; Michael Franti; Elizabeth Michael; Thomas Ketas; Rogier W Sanders; Paul J Maddon; William C Olson; John P Moore
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

6.  Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.

Authors:  P W Parren; P A Marx; A J Hessell; A Luckay; J Harouse; C Cheng-Mayer; J P Moore; D R Burton
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

7.  Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccines.

Authors:  H Sakurai; R A Williamson; J E Crowe; J A Beeler; P Poignard; R B Bastidas; R M Chanock; D R Burton
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

Review 8.  Antibodies in human infectious disease.

Authors:  P W Parren; P Poignard; H J Ditzel; R A Williamson; D R Burton
Journal:  Immunol Res       Date:  2000       Impact factor: 4.505

9.  Identification of CD4-Binding Site Dependent Plasma Neutralizing Antibodies in an HIV-1 Infected Indian Individual.

Authors:  Lubina Khan; Muzamil Ashraf Makhdoomi; Sanjeev Kumar; Ambili Nair; Raiees Andrabi; Brenda E Clark; Kate Auyeung; Jayanta Bhattacharya; Madhu Vajpayee; Naveet Wig; Ralph Pantophlet; Kalpana Luthra
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

10.  Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1.

Authors:  P W Parren; M Wang; A Trkola; J M Binley; M Purtscher; H Katinger; J P Moore; D R Burton
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.